17 results on '"Loeuille, Guy-André"'
Number of results to display per page
Search Results
2. Toward the Standardization of Mycological Examination of Sputum Samples in Cystic Fibrosis: Results from a French Multicenter Prospective Study
- Author
-
Coron, Noémie, Pihet, Marc, Fréalle, Emilie, Lemeille, Yolande, Pinel, Claudine, Pelloux, Hervé, Gargala, Gilles, Favennec, Loic, Accoceberry, Isabelle, Durand-Joly, Isabelle, Dalle, Frédéric, Huet, Frédéric, Fanton, Annlyse, Boldron, Amale, Loeuille, Guy-André, Domblides, Philippe, Coltey, Bérengère, Pin, Isabelle, Llerena, Catherine, Troussier, Françoise, Person, Christine, Marguet, Christophe, Wizla, Nathalie, Thumerelle, Caroline, Turck, Dominique, Bui, Stéphanie, Fayon, Michael, Duhamel, Alain, Prévotat, Anne, Wallaert, Benoit, Leroy, Sylvie, Bouchara, Jean-Philippe, and Delhaes, Laurence
- Published
- 2017
- Full Text
- View/download PDF
3. Changes in Lung Function in Young Cystic Fibrosis Patients Between Two Courses of Intravenous Antibiotics Against Pseudomonas aeruginosa
- Author
-
Béghin, Laurent, Michaud, Laurent, Loeuille, Guy-André, Wizla-Derambure, Nathalie, Sayah, Hocine, Sardet, Anne, Thumerelle, Caroline, Deschildre, Antoine, Turck, Dominique, and Gottrand, Frederic
- Published
- 2009
- Full Text
- View/download PDF
4. 11p15 Imprinting Center Region 1 Loss of Methylation Is a Common and Specific Cause of Typical Russell-Silver Syndrome: Clinical Scoring System and Epigenetic-Phenotypic Correlations
- Author
-
Netchine, Irène, Rossignol, Sylvie, Dufourg, Marie-Noëlle, Azzi, Salah, Rousseau, Alexandra, Perin, Laurence, Houang, Muriel, Steunou, Virginie, Esteva, Blandine, Thibaud, Nathalie, Demay, Marie-Charles Raux, Danton, Fabienne, Petriczko, Elzbieta, Bertrand, Anne-Marie, Heinrichs, Claudine, Carel, Jean-Claude, Loeuille, Guy-André, Pinto, Graziella, Jacquemont, Marie-Line, Gicquel, Christine, Cabrol, Sylvie, and Le Bouc, Yves
- Published
- 2007
5. Toward the Standardization of Mycological Examination of Sputum Samples in Cystic Fibrosis : Results from a French Multicenter Prospective Study
- Author
-
Lafarge, Céline, Pontoire, Bruno, Cayot, Nathalie, Le Bail, Patricia, Coron, Noémie, Pihet, Marc, Fréalle, Emilie, Lemeille, Yolande, Pinel, Claudine, Pelloux, Hervé, Gargala, Gilles, Favennec, Loïc, Accoceberry, Isabelle, Durand-Joly, Isabelle, Dalle, Frédéric, Huet, Frédéric, Fanton, Annlyse, Boldron, Amale, Loeuille, Guy-André, Domblides, Philippe, Coltey, Bérengère, Pin, Isabelle, Llerena, Catherine, Troussier, Françoise, Person, Christine, Marguet, Christophe, Wizla, Nathalie, Thumerelle, Caroline, Turck, Dominique, Bui, Stéphanie, Fayon, Michael, Duhamel, Alain, Prévotat, Anne, Leroy, Sylvie, Wallaert, Benoit, Bouchara, Jean-Philippe, Delhaes, Laurence, Procédés Alimentaires et Microbiologiques [Dijon] (PAM), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Unité de recherche sur les Biopolymères, Interactions Assemblages (BIA), Institut National de la Recherche Agronomique (INRA), Agroécologie [Dijon], Université de Bourgogne (UB)-Institut National de la Recherche Agronomique (INRA)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, ATOMycA (CRCINA-ÉQUIPE 6), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), Université d'Angers (UA), Laboratoire de Parasitologie et Mycologie (Parasito - Myco - LILLE), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université Grenoble Alpes - UFR Pharmacie (UGA UFRP), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Pôle Biologie, Institut de Biologie et Pathologie, Centre Hospitalier Universitaire de Grenoble, Laboratoire de parasitologie-mycologie, CHU Grenoble, CHU Rouen, Normandie Université (NU), Appareil Digestif Environnement Nutrition (ADEN ), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Laboratoire Interactions Muqueuses Agents Transmissibles (LIMA), Université de Bourgogne (UB), Service de pédiatrie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre de Ressources et de Compétences de la Mucoviscidose [CHU Dijon] (CRCM ), CHU Bordeaux, Ctr Rech Mucoviscidose CRCM Adulte, CHU Bordeaux [Bordeaux], CRCM Adulte [Grenoble], Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de pédiatrie générale et maladies infectieuses, Service de Pneumologie Pédiatrique [Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Centre Robert Debré, PRES Université Nantes Angers Le Mans (UNAM), Service de pédiatrie médicale et médecine de l'adolescent [Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Clinique de Pédiatrie, Hôpital Jeanne de Flandre [Lille]-Université de Lille, Hôpital Jeanne de Flandre [Lille], Pediatrics, CHU Bordeaux, Dept Pediat CRCM, INSERM Ctr Invest Clin CIC5, Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Institut d'Informatique et de Mathématiques Appliquées de Grenoble (IMAG), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National Polytechnique de Grenoble (INPG)-Centre National de la Recherche Scientifique (CNRS), Département de Pneumologie, Hôpital A. Calmette, Centre Hospitalier Universitaire de Nice (CHU de Nice), Service de Pneumologie et Immuno-Allergologie [CHU LIlle], Pole Cardio-vasculaire et pulmonaire [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Parasitologie et de Mycologie [Lille], Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] (CRCTB), Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), French Ministry of Health and Research (PHRC N°2006/1902), the association 'Vaincre la Mucoviscidose' (Defeat Cystic Fibrosis) (MucoFong and Mucofong-ATF N8 2006/351), the Pharmaceutical Division of Pfizer France (Nu 2006/158), Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Université Bourgogne Franche-Comté [COMUE] (UBFC), FLAveur, VIsion et Comportement du consommateur (FLAVIC), Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB)-Etablissement National d'Enseignement Supérieur Agronomique de Dijon (ENESAD), ATIP AVENIR / ATOMycA (CRCINA - Département INCIT - Equipe 6), Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers (CRCINA), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Groupe d'Etude des Interactions Hôte-Parasite (GEIHP), Université Grenoble Alpes (UGA), Service de Pédiatrie, Centre de Ressources et de Compétences de la Mucoviscidose [Dijon], Service de Pneumologie et Immuno-Allergologie, Centre hospitalier universitaire de Nantes (CHU Nantes)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes (UN)-Université d'Angers (UA)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes (UN)-Université d'Angers (UA), Service de Parasitologie-Mycologie [CHRU LIlle], Institut de Microbiologie [CHRU Lille], Pôle de Biologie Pathologie Génétique [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Pôle de Biologie Pathologie Génétique [CHU Lille], Centre Hospitalier Universitaire [Grenoble] (CHU), université de Bourgogne, PAM, Hôpital Charles Nicolle [Rouen], Université de Bordeaux (UB), CH Dunkerque, Centre de Recherche en Chimie Moléculaire (CRCM), Université Sciences et Technologies - Bordeaux 1 (UB)-Centre National de la Recherche Scientifique (CNRS), Groupe de Recherche sur les Antimicrobiens et les Micro-Organismes (GRAM 1.0), CHU Lille, CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Etudes et de Recherche en Informatique Médicale [Lille] (CERIM), Hôpital Pasteur [Nice] (CHU), Centre Hospitalier Universitaire de Nice (CHU Nice), Procédés Alimentaires et Microbiologiques [Dijon] ( PAM ), Université de Bourgogne ( UB ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Université Bourgogne Franche-Comté ( UBFC ), Unité de recherche sur les Biopolymères, Interactions Assemblages ( BIA ), Institut National de la Recherche Agronomique ( INRA ), FLAveur, VIsion et Comportement du consommateur ( FLAVIC ), Etablissement National d'Enseignement Supérieur Agronomique de Dijon ( ENESAD ) -Institut National de la Recherche Agronomique ( INRA ) -Université de Bourgogne ( UB ), ATIP AVENIR / ATOMycA ( CRCINA - Département INCIT - Equipe 6 ), Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers ( CRCINA ), Université d'Angers ( UA ) -Université de Nantes ( UN ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche en Santé de l'Université de Nantes ( IRS-UN ) -Centre hospitalier universitaire de Nantes ( CHU Nantes ) -Université d'Angers ( UA ) -Université de Nantes ( UN ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche en Santé de l'Université de Nantes ( IRS-UN ) -Centre hospitalier universitaire de Nantes ( CHU Nantes ), Groupe d'Etude des Interactions Hôte-Parasite ( GEIHP ), Université d'Angers ( UA ), Laboratoire de Parasitologie et Mycologie ( Parasito - Myco - LILLE ), Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Université Grenoble Alpes - UFR Pharmacie ( UGA UFRP ), Université Grenoble Alpes ( UGA ), Appareil Digestif Environnement Nutrition ( ADEN ), Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Microbiologie cellulaire et moléculaire et pathogénicité ( MCMP ), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique ( CNRS ), Laboratoire Interactions Muqueuses Agents Transmissibles ( LIMA ), Université de Bourgogne ( UB ), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Institut d'oncologie/développement Albert Bonniot de Grenoble ( INSERM U823 ), Université Joseph Fourier - Grenoble 1 ( UJF ) -CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier Universitaire d'Angers-Centre Robert Debré, Centre Hospitalier Universitaire d'Angers ( CHU Angers ), PRES Université Nantes Angers Le Mans ( UNAM ), CHU Rouen-Université de Rouen Normandie ( UNIROUEN ), Université de Bordeaux ( UB ) -CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier Universitaire de Bordeaux, Institut d'Informatique et de Mathématiques Appliquées de Grenoble ( IMAG ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut National Polytechnique de Grenoble ( INPG ) -Centre National de la Recherche Scientifique ( CNRS ), Centre Hospitalier Universitaire de Nice ( CHU de Nice ), Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] ( CRCTB ), and Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale ( INSERM )
- Subjects
Adult ,Male ,Microbiological Techniques ,0301 basic medicine ,medicine.medical_specialty ,Filamentous fungi ,Adolescent ,Veterinary (miscellaneous) ,Lung mycobiota ,030106 microbiology ,Biology ,Applied Microbiology and Biotechnology ,Microbiology ,Cystic fibrosis ,Aspergillus fumigatus ,Molds ,Young Adult ,03 medical and health sciences ,Medical microbiology ,Exophiala ,Mycological examination ,medicine ,Humans ,Prospective Studies ,Child ,Candida albicans ,[ SDV.MP.MYC ] Life Sciences [q-bio]/Microbiology and Parasitology/Mycology ,[SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology ,Aged ,Aged, 80 and over ,Aspergillus ,Lung Diseases, Fungal ,Fungi ,Sputum ,Scedosporium apiospermum ,Middle Aged ,biology.organism_classification ,[SDV.MP.MYC] Life Sciences [q-bio]/Microbiology and Parasitology/Mycology ,Corpus albicans ,030104 developmental biology ,Female ,France ,medicine.symptom ,Agronomy and Crop Science - Abstract
IF 1.710; International audience; Fungal respiratory colonization of cystic fibrosis (CF) patients emerges as a new concern; however, the heterogeneity of mycological protocols limits investigations. We first aimed at setting up an efficient standardized protocol for mycological analysis of CF sputa that was assessed during a prospective, multicenter study: “MucoFong” program (PHRC-06/1902). Sputa from 243 CF patients from seven centers in France were collected over a 15-month period and submitted to a standardized protocol based on 6 semi-selective media. After mucolytic pretreatment, sputa were plated in parallel on cycloheximide-enriched (ACT37), erythritol-enriched (ERY37), benomyl dichloran–rose bengal (BENO37) and chromogenic (CAN37) media incubated at 37 °C and on Sabouraud–chloramphenicol (SAB27) and erythritol-enriched (ERY27) media incubated at 20–27 °C. Each plate was checked twice a week during 3 weeks. Fungi were conventionally identified; time for detection of fungal growth was noted for each species. Fungal prevalences and media performances were assessed; an optimal combination of media was determined using the Chi-squared automatic interaction detector method. At least one fungal species was isolated from 81% of sputa. Candida albicans was the most prevalent species (58.8%), followed by Aspergillus fumigatus (35.4%). Cultivation on CAN37, SAB27, ACT37 and ERY27 during 16 days provided an optimal combination, detecting C. albicans, A. fumigatus, Scedosporium apiospermum complex and Exophiala spp. with sensitivities of 96.5, 98.8, 100 and 100%. Combination of these four culture media is recommended to ensure the growth of key fungal pathogens in CF respiratory specimens. The use of such consensual protocol is of major interest for merging results from future epidemiological studies.
- Published
- 2018
- Full Text
- View/download PDF
6. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial
- Author
-
Ballmann, Manfred, primary, Hubert, Dominique, additional, Assael, Baroukh M, additional, Staab, Doris, additional, Hebestreit, Alexandra, additional, Naehrlich, Lutz, additional, Nickolay, Tanja, additional, Prinz, Nicole, additional, Holl, Reinhard W, additional, Staden, Ute, additional, Claßen, Martin, additional, Schuster, Antje, additional, Mellies, Uwe, additional, Posselt, Hans-Georg, additional, Wiebel, Matthias, additional, Rietschel, Ernst, additional, Stern, Martin, additional, Teschler, Helmut, additional, Smaczny, Christina, additional, Köhnlein, Thomas, additional, Wienhausen-Wilke, Vera, additional, Claaß, Andreas, additional, Biedermann, Thomas, additional, Dockter, Gerd, additional, Köster, Holger, additional, Hebestreit, Helge, additional, Ballke, Ernst-Hinrich, additional, Heuer, Hans-Eberhard, additional, Kamin, Wolfgang, additional, Küster, Peter, additional, Szczepanski, Rüdiger, additional, Keller, Klaus-Michael, additional, Generlich, Horst, additional, Bresser, Hans-Georg, additional, Kopp, Matthias, additional, Herting, Egbert, additional, Feickert, Hans-Joachim, additional, Hautz, Jürgen, additional, Schilling, Birgit, additional, Meyer, Egbert, additional, Mall, Marcus A, additional, Wiebicke, Wolfram, additional, Tegtmeyer, Friedrich-Karl, additional, Honer, Marguerite, additional, Mosnier-Pudar, Helen, additional, Lenoir, Gérard, additional, Robert, Jean-Jacques, additional, Kessler, Laurence, additional, Weiss, Laurence, additional, Nove-Josserand, Raphaële, additional, Vantyghem, Marie-Christine, additional, Munck, Anne, additional, Wizla, Nathalie, additional, Leroy, Sylvie, additional, Loeuille, Guy-André, additional, Serreau, Raphaël, additional, Aissat, Fawzia, additional, Thalhammer, Gabriela H, additional, Huttegger, Isidor, additional, Eichler, Irmgard, additional, and Götz, Manfred, additional
- Published
- 2018
- Full Text
- View/download PDF
7. Chronic Aspergillus fumigatus colonization of respiratory tract in Cystic Fibrosis: Diagnosis, management and antifungal resistance in a French cohort of CF patients
- Author
-
Delhaès, Laurence, Jourdain, A., d'Almeida-Fourquet, M., Fréalle, Emilie, Leroy, Sylvie, Pinel, Claudine, Coltey, Bérengère, Favennec, Loïc, Dominique, S., Vagner, O., Fanton, Annlyse, Bouchara, Jean-Philippe, Person, Christine, Durand-Joly, Isabelle, Loeuille, Guy-André, Domblides, Philippe, Accoceberry, Isabelle, Farce, A., Chavatte, P., Wallaert, Benoit, Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), and Université d'Angers (UA)
- Subjects
[SDV]Life Sciences [q-bio] - Abstract
Titre abrégé : Chronic Aspergillus fumigatus colonisation of respiratory tract in cystic fibrosis: diagnosis, management and antifungal resistance in a French cohort of cystic fibrosis patients; International audience; Introduction:Cystic fibrosis (CF) is the major genetic inherited diseasein the European Caucasian population, with an average of 1 in 3000 living births in France. Prognostic depend essentially on the lung impairments. While considerable attention therefore has been paid over recent decades to prevent and treat bacterial respiratory infections, we observed emergence of fungi colonization in CF respiratory tract. In particular, Aspergillus fumigatus represents the most common causative agent colonizing the airways of CF patients; it can be responsible for Allergic Bronchopulmonary Aspergillosis (ABPA). Sinceoral corticosteroids and itraconazole represent the mainstay of ABPA treatment, long-term therapy may increase the risk of acquired resistance to azoles that is mainly associated with amino acid substitutions in the CYP51A gene of A. fumigatus.Objective: Because CF patients are chronically exposed to itraconazole, our study aimed to evaluate the prevalence of azole resistance in isolates prospectively collected from CF patients followed-up in seven French hospitals involved in our national prospective study (“MucoFong” study − PHRC1902). To our knowledge, it is the first multicenter studyfocused on azole resistance of A. fumigatus in CF.Methods: A total of 87 isolates of A. fumigatus was collected in 85 patients. The MICs of azole drugs were evaluated for each isolate using the E-test ® strips. Isolates were characterized at the molecular level by targeting ITS, b-tubulin and MAT-A/a genes. The cyp51A gene as well as its promoter was sequenced.Results and Discussion:A majority of isolates (88.1%) were found sensitive to itraconazole (MIC 2 mg/ml), and 2 new mutations were identified and localized within 3-dimensional Cyp51A protein model. To obtain insight into azole resistance of A. fumigatus, the results are analyzed taking into account clinical data, itraconazole exposition, and the potential correlation between the identified CYP5IA mutations and azole resistance is discussed based on the Cyp51A protein homology model.
- Published
- 2011
- Full Text
- View/download PDF
8. Fungal colonization in Cystic Fibrosis (CF): Epidemiology and antifungal resistance in a French cohort of CF patients – Focused on Aspergillus fumigatus colonization
- Author
-
Delhaès, Laurence, d'Almeida-Fourquet, M., Fréalle, Emilie, Leroy, Stéphane, Pinel, Claudine, Llerana, C., Favennec, Loïc, Dominique, S., Vagner, O., Fanton, Annlyse, Bouchara, Jean-Philippe, Person, Christine, Durand-Joly, Isabelle, Loeuille, Guy-André, Domblides, Philippe, Accoceberry, Isabelle, Farce, A., Chavatte, P., Wallaert, Benoit, Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), and Université d'Angers (UA)
- Subjects
Exophiala spp ,Scedosporium apiospermum ,Aspergillus fumigatus ,[SDV]Life Sciences [q-bio] ,antifungal resistance ,Cystic fibrosis ,Scedosporium prolificans - Abstract
International audience; Introduction: Cystic fibrosis (CF) is the major genetic inherited disease in the European Caucasian population, with an average of 1 in 3000 living births in France. Prognostic dependessentially on the lung impairments. While considerable attention therefore has been paid over recent decades to prevent and treat bacterial respiratory infections, we observed emergence of fungi colonization in CF respiratory tract. In particular, Aspergillus fumigatus represents the most common causative agent colonizing the airways of CF patients; it can be responsible for Allergic Bronchopulmonary Aspergillosis (ABPA). Since oral corticosteroids and itraconazole represent the mainstay of ABPA treatment, long-term therapy may increase the risk of acquired resistance to azoles that is mainly associated with amino acid substitutions in the CYP51A gene of A. fumigatus.Objective: First, we managed to have exhaustive epidemiological data on species of filamentous fungi able to colonize the airway tract of 300 CF patients followed-up in our national prospective study ("MucoFong" study – PHRC1902). Second, CF patients being chronically exposed to azole (especially to itraconazole), our study aimed to evaluate the prevalence of azole resistance in isolates prospectively collected from CF patients followed-up in seven French hospitals involved in our national prospective study. Third, we focused on the most prevalent species: Aspergillus fumigatus, studying the azole resistance at molecular level. To our knowledge, it is the first multicenter study focused on azole resistance of A. fumigatus in CF.Methods:A total of 243 sputa were analyzed using the same protocol in each centre. TheMICs of antifungal drugs were evaluated for each isolate using the E-test ® strips. Focusing on A. fumigatus, a total of 87 isolates was collected in 85 patients. These isolates were characterized at the molecular level by targeting ITS, ß-tubulin and MAT-A/α genes. The CYP51A gene as well as its promoter was sequenced; a 3D Cyp51A protein homology model was built.Results and discussion:300 patients were enrolled in this study. At inclusion time, most of them were adults colonized with A. fumigatus (about 35% of the patients). Scedosporium was isolated in 5%, and Exophiala in about 2%. Regarding antifungal susceptibility, isolates of Scedosporium and Exophiala exhibited antifungal resistance comparable with published data. Regarding A. fumigatus, a majority of isolates (88.1%) were found sensitive to itraconazole (MIC≤ 2μg/ml), and 2 new mutations were identified and localized within 3-dimensional Cyp51A protein model. To obtain insight into azole resistance of A. fumigatus, the results are analyzed taking into account clinical data, itraconazole exposition, and the potential correlation between the identified CYP5IA mutations and azole resistance is discussed based on the Cyp51A protein homology model.
- Published
- 2011
9. An ancient protein-DNA interaction underlying metazoan sex determination
- Author
-
Murphy, Mark W, primary, Lee, John K, additional, Rojo, Sandra, additional, Gearhart, Micah D, additional, Kurahashi, Kayo, additional, Banerjee, Surajit, additional, Loeuille, Guy-André, additional, Bashamboo, Anu, additional, McElreavey, Kenneth, additional, Zarkower, David, additional, Aihara, Hideki, additional, and Bardwell, Vivian J, additional
- Published
- 2015
- Full Text
- View/download PDF
10. Risque fongique chez les patients atteints de mucoviscidose : premier bilan de l’etude nationale multicentrique - PHRC 1902 'MUCOFONG'
- Author
-
Delhaès, Laurence, Fréalle, Emilie, Lemeille, Yolande, Coltey, Bérengère, Gargala, Gilles, Dominique, S., Accoceberry, Isabelle, Domblides, Philippe, Durand-Joly, Isabelle, Loeuille, Guy-André, Vagner, O., Dalle, Frédéric, Fanton, Annlyse, Boldron, Amale, Pinel, Claudine, Llerena, Catherine, Pihet, Marc, Giniès, J.-L., Bouchara, Jean-Philippe, Person, Christine, Wizla, Nathalie, Thumerelle, Caroline, Favennec, Loïc, Marguet, Christophe, Bui, Stéphanie, Leroy, Sylvie, Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), and Université d'Angers (UA)
- Subjects
[SDV]Life Sciences [q-bio] - Published
- 2010
11. Toward the Standardization of Mycological Examination of Sputum Samples in Cystic Fibrosis: Results from a French Multicenter Prospective Study.
- Author
-
Coron, Noémie, Pihet, Marc, Fréalle, Emilie, Lemeille, Yolande, Pinel, Claudine, Pelloux, Hervé, Gargala, Gilles, Favennec, Loic, Accoceberry, Isabelle, Durand-Joly, Isabelle, Dalle, Frédéric, Huet, Frédéric, Fanton, Annlyse, Boldron, Amale, Loeuille, Guy-André, Domblides, Philippe, Coltey, Bérengère, Pin, Isabelle, Llerena, Catherine, and Troussier, Françoise
- Abstract
Fungal respiratory colonization of cystic fibrosis (CF) patients emerges as a new concern; however, the heterogeneity of mycological protocols limits investigations. We first aimed at setting up an efficient standardized protocol for mycological analysis of CF sputa that was assessed during a prospective, multicenter study: 'MucoFong' program (PHRC-06/1902). Sputa from 243 CF patients from seven centers in France were collected over a 15-month period and submitted to a standardized protocol based on 6 semi-selective media. After mucolytic pretreatment, sputa were plated in parallel on cycloheximide-enriched (ACT37), erythritol-enriched (ERY37), benomyl dichloran-rose bengal (BENO37) and chromogenic (CAN37) media incubated at 37 °C and on Sabouraud-chloramphenicol (SAB27) and erythritol-enriched (ERY27) media incubated at 20-27 °C. Each plate was checked twice a week during 3 weeks. Fungi were conventionally identified; time for detection of fungal growth was noted for each species. Fungal prevalences and media performances were assessed; an optimal combination of media was determined using the Chi-squared automatic interaction detector method. At least one fungal species was isolated from 81% of sputa. Candida albicans was the most prevalent species (58.8%), followed by Aspergillus fumigatus (35.4%). Cultivation on CAN37, SAB27, ACT37 and ERY27 during 16 days provided an optimal combination, detecting C. albicans, A. fumigatus, Scedosporium apiospermum complex and Exophiala spp. with sensitivities of 96.5, 98.8, 100 and 100%. Combination of these four culture media is recommended to ensure the growth of key fungal pathogens in CF respiratory specimens. The use of such consensual protocol is of major interest for merging results from future epidemiological studies. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
12. Brief report: 11p15 imprinting center region 1 loss of methylation is a common and specific cause of typical Russell-Silver syndrome: Clinical scoring system and epigenetic-phenotypic correlations
- Author
-
Netchine, Irène, Rossignol, Sylvie, Dufourg, Marie-Noëlle, Azzi, Salah, Rousseau, Alexandra, Perin, Laurence, Houang, Muriel, Steunou, Virginie, Esteva, Blandine, Thibaud, Nathalie, Demay, Marie-Charles Raux M.-C.R., Danton, Fabienne, Petriczko, Elzbieta, Bertrand, Anne-Marie, Heinrichs, Claudine, Carel, Jean-Claude, Loeuille, Guy-André, Pinto, Graziella, Jacquemont, Marie-Line, Gicquel, Christine, Cabrol, Sylvie, Le Bouc, Yves, Netchine, Irène, Rossignol, Sylvie, Dufourg, Marie-Noëlle, Azzi, Salah, Rousseau, Alexandra, Perin, Laurence, Houang, Muriel, Steunou, Virginie, Esteva, Blandine, Thibaud, Nathalie, Demay, Marie-Charles Raux M.-C.R., Danton, Fabienne, Petriczko, Elzbieta, Bertrand, Anne-Marie, Heinrichs, Claudine, Carel, Jean-Claude, Loeuille, Guy-André, Pinto, Graziella, Jacquemont, Marie-Line, Gicquel, Christine, Cabrol, Sylvie, and Le Bouc, Yves
- Abstract
Context: Russell-Silver syndrome (RSS), characterized by intrauterine and postnatal growth retardation, dysmorphic features, and frequent body asymmetry, spares cranial growth. Maternal uniparental disomy for chromosome 7 (mUPD7) is found in 5-10% of cases. We identified loss of methylation (LOM) of 11p15 Imprinting Center Region 1 (ICR1) domain (including IGF-II) as a mechanism leading to RSS. Objective: The aim was to screen for 11p15 epimutation and mUPD7 in RSS and non-RSS small-for-gestational-age (SGA) patients and identify epigenetic-phenotypic correlations. Studied Population and Methods: A total of 127 SGA patients were analyzed. Clinical diagnosis of RSS was established when the criterion of being SGA was associated with at least three of five criteria: postnatal growth retardation, relative macrocephaly, prominent forehead, body asymmetry, and feeding difficulties. Serum IGF-II was evaluated for 82 patients. Results: Of the 127 SGA patients, 58 were diagnosed with RSS; 37 of these (63.8%) displayed partial LOM of the 11p15 ICR1 domain, and three (5.2%) had mUPD7. No molecular abnormalities were found in the non-RSS SGA group (n = 69). Birth weight, birth length, and postnatal body mass index (BMI) were lower in the abnormal 11p15 RSS group (ab-ICR1-RSS) than in the normal 11p15 RSS group [-3.4 vs. -2.6 SD score (SDS), -4.4 vs. -3.4 SDS, and -2.5 vs. -1.6 SDS, respectively; P < 0.05]. Among RSS patients, prominent forehead, relative macrocephaly, body asymmetry, and low BMI were significantly associated with ICR1 LOM. All ab-ICR1-RSS patients had at least four of five criteria of the scoring system. Postnatal IGF-II levels were within normal values. Conclusion: The 11p15 ICR1 epimutation is a major, specific cause of RSS exhibiting failure to thrive. We propose a clinical scoring system (including a BMI < -2 SDS), highly predictive of 11p15 ICR1 LOM, for the diagnosis of RSS. Copyright © 2007 by The Endocrine Society., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2007
13. Impact of Intravenous Antibiotic Therapy on Total Daily Energy Expenditure and Physical Activity in Cystic Fibrosis Children with Pseudomonas aeruginosa Pulmonary Exacerbation
- Author
-
Béghin, Laurent, primary, Gottrand, Frédéric, additional, Michaud, Laurent, additional, Loeuille, Guy-André, additional, Wizla-Derambure, Nathalie, additional, Sardet, Anne, additional, Guimber, Dominique, additional, Deschildre, Antoine, additional, and Turck, Dominique, additional
- Published
- 2003
- Full Text
- View/download PDF
14. The CEMHaVi Program
- Author
-
Vanhelst, Jérémy, Marchand, Frédéric, Fardy, Paul, Zunquin, Gautier, Loeuille, Guy-André, Renaut, Hervé, Mikulovic, Jacques, Hurdiel, Rémy, Béghin, Laurent, and Theunynck, Denis
- Abstract
Obesity in children has increased in recent years. Many studies with differing methodologies have been undertaken to treat obesity. The Control, Evaluation, and Modification of Lifestyles in Obese Youth (CEMHaVi) program is a unique 2-year health-wellness program of physical activity and health education for obese youth. Findings of this study represent results at 1-year follow-up. The purpose of this study was to evaluate the effects of the CEMHaVi program.
- Published
- 2010
- Full Text
- View/download PDF
15. Impact of Intravenous Antibiotic Therapy on Total Daily Energy Expenditure and Physical Activity in Cystic Fibrosis Children with Pseudomonas aeruginosaPulmonary Exacerbation
- Author
-
BÉGHIN, LAURENT, GOTTRAND, FRÉDÉRIC, MICHAUD, LAURENT, LOEUILLE, GUY-ANDRÉ, WIZLA-DERAMBURE, NATHALIE, SARDET, ANNE, GUIMBER, DOMINIQUE, DESCHILDRE, ANTOINE, AND, and TURCK, DOMINIQUE
- Abstract
Resting energy expenditure (REE) increases during pulmonary exacerbation by Pseudomonas aeruginosain cystic fibrosis (CF) patients, and decreases after i.v. anti-Pseudomonas aeruginosaantibiotic therapy (IVAT). However, the impact of IVAT on total energy expenditure (TEE) is unknown. The aim of this study was to assess the changes in TEE and its main components after IVAT administered at home. Body composition measured by skinfold thickness and bio-impedance analysis, energy intake (EI) assessed by a weekly diary, REE measured by indirect calorimetry (IC), TEE assessed by a technique using 24-h heart-rate monitoring method and physical activity (PA) monitored using an activity diary (AD) were assessed in 16 patients (9 boys and 7 girls) aged 12.1 ± 2.3 y (range, 7.1–14.6 y), before and after 28 ± 4 d including a 14-d IVAT course. After IVAT, weight increased significantly by 1.9 (32.1 ± 7.5 versus32.7 ± 7.6 kg; p< 0.05), while fat mass and fat free mass increased non significantly. EI increased by 4.6 (10,797 ± 3,039 versus11,320 ± 3,074 kJ/d; p< 0.05). TEE was not affected by IVAT (7,014 ± 1,929 versus7,081 ± 1,478 kJ/d) whereas REE decreased by 4.1 (5,295 ± 909 versus5,093 ± 837 kJ/d; p< 0.05), resulting in 9.3 increase in PA assessed by AD converted to metabolic equivalent tasks (MET) (37.0 ± 3.1 versus40.7 ± 4.5 MET; p< 0.05). The improvement in nutritional status after IVAT is not related to a decrease in TEE, but probably to an increase in EI and a decrease of REE after IVAT. After IVAT, the reduction in REE is probably compensated by an increase in PA in CF patients.
- Published
- 2003
- Full Text
- View/download PDF
16. Association of environmental markers with childhood type 1 diabetes mellitus revealed by a long questionnaire on early life exposures and lifestyle in a case-control study.
- Author
-
Balazard F, Le Fur S, Valtat S, Valleron AJ, Bougnères P, Thevenieau D, Chatel CF, Desailloud R, Bony-Trifunovic H, Ducluzeau PH, Coutant R, Caudrelier S, Pambou A, Dubosclard E, Joubert F, Jan P, Marcoux E, Bertrand AM, Mignot B, Penformis A, Stuckens C, Piquemal R, Barat P, Rigalleau V, Stheneur C, Fournier S, Kerlan V, Metz C, Fargeot-Espaliat A, Reznic Y, Olivier F, Gueorguieva I, Monier A, Radet C, Gajdos V, Terral D, Vervel C, Bendifallah D, Signor CB, Dervaux D, Benmahammed A, Loeuille GA, Popelard F, Guillou A, Benhamou PY, Khoury J, Brossier JP, Bassil J, Clavel S, Le Luyer B, Bougnères P, Labay F, Guemas I, Weill J, Cappoen JP, Nadalon S, Lienhardt-Roussie A, Paoli A, Kerouedan C, Yollin E, Nicolino M, Simonin G, Cohen J, Atlan C, Tamboura A, Dubourg H, Pignol ML, Talon P, Jellimann S, Chaillous L, Baron S, Bortoluzzi MN, Baechler E, Salet R, Zelinsky-Gurung A, Dallavale F, Larger E, Laloi-Michelin M, Gautier JF, Guérin B, Oilleau L, Pantalone L, Lukas C, Guilhem I, De Kerdanet M, Wielickzo MC, Priou-Guesdon M, Richard O, Kurtz F, Laisney N, Ancelle D, Parlier G, Boniface C, Bockel DP, Dufillot D, Razafimahefa B, Gourdy P, Lecomte P, Pepin-Donat M, Combes-Moukhovsky ME, Zymmermann B, Raoulx M, and Dumont AG
- Abstract
Background: The incidence of childhood type 1 diabetes (T1D) incidence is rising in many countries, supposedly because of changing environmental factors, which are yet largely unknown. The purpose of the study was to unravel environmental markers associated with T1D., Methods: Cases were children with T1D from the French Isis-Diab cohort. Controls were schoolmates or friends of the patients. Parents were asked to fill a 845-item questionnaire investigating the child's environment before diagnosis. The analysis took into account the matching between cases and controls. A second analysis used propensity score methods., Results: We found a negative association of several lifestyle variables, gastroenteritis episodes, dental hygiene, hazelnut cocoa spread consumption, wasp and bee stings with T1D, consumption of vegetables from a farm and death of a pet by old age., Conclusions: The found statistical association of new environmental markers with T1D calls for replication in other cohorts and investigation of new environmental areas., Trial Registration: Clinical-Trial.gov NCT02212522 . Registered August 6, 2014.
- Published
- 2016
- Full Text
- View/download PDF
17. The CEMHaVi program: control, evaluation, and modification of lifestyles in obese youth.
- Author
-
Vanhelst J, Marchand F, Fardy P, Zunquin G, Loeuille GA, Renaut H, Mikulovic J, Hurdiel R, Béghin L, and Theunynck D
- Subjects
- Achievement, Adolescent, Body Mass Index, Child, Female, Follow-Up Studies, France, Health Knowledge, Attitudes, Practice, Humans, Male, Obesity epidemiology, Sleep, Health Education, Life Style, Motor Activity, Obesity therapy, Program Evaluation
- Abstract
Purpose: Obesity in children has increased in recent years. Many studies with differing methodologies have been undertaken to treat obesity. The Control, Evaluation, and Modification of Lifestyles in Obese Youth (CEMHaVi) program is a unique 2-year health-wellness program of physical activity and health education for obese youth. Findings of this study represent results at 1-year follow-up. The purpose of this study was to evaluate the effects of the CEMHaVi program., Methods: Physician-referred subjects (N = 26) participated in the study, 14 girls (13.4 +/- 2.9 years) and 12 boys (12.3 +/- 2.8 years). Measurements included height, weight, body mass index (BMI), academic performance, sleep habits, and health knowledge. The intervention consisted of a unique program of physical activity, including a variety of games specifically selected to be enjoyable, maintain interest, and motivate subjects to adhere. Activity sessions were offered once per week, 2 hours each session, for 12 months. A health education program was offered once every 3 months for 2 hours per session. Health knowledge, academic performance, self-esteem, and sleep were assessed before and after the intervention. Means were calculated at baseline and following intervention and were compared by paired t tests., Results: Findings suggest significant improvements in academic performance (P < .001), quality and quantity of sleep (P < .05), and obesity (P < .05)., Conclusions: The program reduced BMI and improved health knowledge, sleep, and academic performance in obese children. The feasibility of a beneficial lifestyle intervention program is encouraging in addressing obesity and related issues in young boys and girls.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.